Von Willebrand Disease Treatment Market

Von Willebrand Disease Treatment Market (Disease Type: Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease, and Acquired von Willebrand Disease; Drug: Desmopressin, Clot-stabilizing Medications, Replacement Therapies, Contraceptives, and Others; Route of Administration: Oral, Injection, and Others; Gender: Men and Women; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Surge in Government Initiatives and Awareness Pertaining to Von Willebrand Disease Treatment to Aid Market Growth

Although the von Willebrand disease is relatively rare, it is one of the most common bleeding disorders. Diagnosis and von Willebrand diseases treatment around the world continue to vary due to which, several key players operating in the current von Willebrand disease treatment market landscape are increasingly seeking opportunities to collaborate with other players involved, and redefine current norms and guidelines pertaining to the von Willebrand diseases treatment. Several major government and private sector organizations are forging strategic alliances to increase efficacy and success rate of existing and upcoming treatments.

Clinical guidelines laid down by the World Federation of Hemophilia (WFH) are recognized worldwide and implemented by healthcare providers. Although the guidelines issued by the WFH are largely relied upon, efforts are being made to maintain state-of-the-art guidelines for von Willebrand disease. Research and development activities are expected to play a major role in boosting the overall prospects of the global von Willebrand disease treatment market during the forecast period, and also pave the path for new therapies and diagnostics framework. Players operating in the current von Willebrand disease treatment market are projected to focus on drug development, refine existing therapies, and gain approval from the FDA for their advancements.

At the back of these factors, the global von Willebrand disease treatment market is expected to attain a market value of ~US$ 900 Mn by the end of 2030. In addition, increasing support from governments, rise in government initiatives, and surge in demand for recombinant therapies are factors that are likely to aid the growth of the market for von Willebrand disease treatment during the assessment period.

Efforts to Standardize von Willebrand Disease Treatment Worldwide Likely to Increase Collaborations

While research and development activities are likely to gain considerable momentum in the upcoming years, collaborations between regulatory bodies around the world are projected to witness considerable growth as efforts are in full swing to standardize the diagnostics and von Willebrand disease treatment worldwide. Collaborations and joint ventures are also on the rise, particularly to streamline drug development and curate clinical guidelines. For instance, the American Society of Hematology (ASH), the National Hemophilia Foundation (NHF), and the International Society on Thrombosis and Haemostasis (ISTH) entered a collaboration with each other to develop clinical guidelines due to the glaring differences in diagnosis and treatment practices of von Willebrand disease worldwide. As such, collaborations continue to rise across the von Willebrand disease treatment market, the quality and efficacy of von Willebrand disease treatment is likely to grow in the forthcoming decade– a major factor that is expected to accelerate the growth of the von Willebrand disease treatment market.

Advent of New Therapies for von Willebrand Disease Likely to Boost Market Growth

Research and development activities are set to play an important role in augmenting the growth of the global von Willebrand disease treatment market during the assessment period. The entry of new therapies and von Willebrand disease treatment, as a result of research programs and initiatives, is expected to provide a considerable boost to the global von Willebrand disease treatment market. Majorly, the management of von Willebrand disease is mainly based on the dual correction of primary hemostasis defect caused due to inherited deficiency of von Willebrand factor (VWF) and the secondary defect factor VIII coagulant activity. At present, new therapies are aimed toward addressing primary deficiency in the von Willebrand disease. Considerable research is being carried out to evaluate the efficacy of new products in different clinical situations. In addition, scientists and researchers are also focusing on testing the efficacy of new therapies and products in unexplored situations, including long-term use of prophylaxis, use in children, and during recurrent gastrointestinal bleeding.

Market Growth to Remain Steady amid COVID-19 Pandemic

The ongoing COVID-19 pandemic is expected to have a short-term impact on the overall growth of the global von Willebrand disease treatment market. Although the sales of medication and adoption of various therapies could see a slight dip due to the COVID-19 situation, research and development activities are expected to continue in full swing across the von Willebrand disease treatment market. Several research institutes around the world are increasingly assessing the relationship between von Willebrand disease and COVID-19 due to which, new areas pertaining to von Willebrand disease treatment are being explored. While drug development and research activities are likely to remain unaffected, the number of clinical tests and procedures could potentially witness a slight dip in 2020.

Analysts’ Viewpoint

The global von Willebrand disease treatment market is expected to expand at a healthy CAGR of ~6% during the forecast period. The market growth is largely driven by factors, including increasing collaborations and partnerships between top-tier research institutes and regulatory bodies, entry of new von Willebrand disease therapies, and growing awareness related to von Willebrand disease due to a surge in the number of government initiatives and awareness programs. While research and development activities are set to play an imperative role in the expansion of the von Willebrand disease treatment market, other factors that are likely to influence the market growth include rise in demand for recombinant therapies and strong product pipeline.  

Von Willebrand Disease Treatment Market: Overview

  • Von Willebrand disease is an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF). VWF is a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury. This protein also binds to clotting factor VIII (FVIII) in the circulation and stabilizes it.
  • Symptoms of von Willebrand disease include prolonged bleeding from skin lacerations, bleeding from nose and gums, and menorrhagia
  • The global von Willebrand disease treatment market has expanded significantly in the last decade due to rise in the number of patient assistance programs and promising drug pipeline & approvals
  • Different types of therapeutics have been utilized in the treatment of von Willebrand disease, including desmopressin, clot-stabilizing medications, replacement therapies, contraceptives, and others. Desmopressin is extensively used in the treatment of von Willebrand disease.

Von Willebrand Disease Treatment Market Drivers

  • Several companies, associations, and organizations are introducing different patient assistance programs for those who have been affected with von Willebrand disease or other bleeding disorders. These patient assistance programs have impacted the von Willebrand disease treatment in a positive way in terms of increase in awareness about the disease, diagnosis, and treatment. This, in turn, has fueled the global von Willebrand disease treatment market. For instance, in June 2020, Octapharma AG partnered with Domedica to develop the WiCare program in order to provide home support to patients suffering from von Willebrand disease (vWD).
  • Rich product pipeline and recent approval of drugs to treat von Willebrand disease are expected to drive the global von Willebrand disease market during the forecast period. In September 2018, Shire plc (now Takeda) received marketing authorization from the European Union for Veyvondi for adults with von Willebrand disease.

Market Segmentation: Von Willebrand Disease Treatment Market

  • Based on disease type, the global von Willebrand disease treatment market has been divided into type 1 von Willebrand disease, type 2 von Willebrand disease, type 3 von Willebrand disease, and acquired von Willebrand disease. The type 1 von Willebrand disease segment is likely to dominate the global von Willebrand disease treatment market during the forecast period.
  • In terms of drug, the global von Willebrand disease treatment market has been bifurcated into desmopressin, clot-stabilizing medications, replacement therapies, contraceptives, and others
  • In terms of route of administration, the global von Willebrand disease treatment market has been categorized into oral, injection, and others
  • In terms of gender, the global von Willebrand disease treatment market has been categorized into men and women
  • In terms of distribution channel, the global von Willebrand disease market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global von Willebrand disease market, in terms of revenue, in 2019.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Von Willebrand Disease Treatment Market

  • In terms of region, the global von Willebrand disease treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and expected market value (US$ Mn) of these regional markets and their major countries have been provided in the report from 2018 to 2030, with their CAGRs from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the global von Willebrand disease treatment market, which would help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process

Major Players

  • The von Willebrand disease treatment market report concludes with the company profiles section, which includes key information about major players in the global von Willebrand disease treatment market
  • Leading players analyzed in the von Willebrand disease treatment market report include 
    • Octapharma AG
    • Grifols, S.A.
    • Shire plc
    • Bayer AG
    • CSL Behring
    • Pfizer, Inc.
    • Akorn, Inc.
    • Ferring B.V.
  • Each of these players has been profiled in the von Willebrand disease treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Frequently Asked Questions

What is the total market worth of von willebrand disease treatment market?

von willebrand disease treatment market is expected to attain a market value of ~US$ 900 Mn by the end of 2030

What is the anticipated CAGR of the von willebrand disease treatment market in the forecast period?

von Willebrand disease treatment market is expected to expand at a healthy CAGR of ~6% during 2020 - 2030

What are the key driving factors for the growth of the von willebrand disease treatment market?

von Willebrand disease treatment market is driven by rise in government initiatives and surge in demand for recombinant therapies

Which region is expected to project the highest market share in the global von willebrand disease treatment market?

North America accounted for a major share of the global von Willebrand disease treatment market and this trend is anticipated to continue during the forecast period

Who are the key players in the global von willebrand disease treatment market?

Key players operating in the global von Willebrand disease treatment market include Octapharma AG, Grifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., and Ferring B.V.

1. Preface

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Research Methodology 

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Key Industry Developments

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity

    4.4. Global Von Willebrand Disease Treatment Market Forecast

    4.5. Global Von Willebrand Disease Treatment Market Outlook

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Disease Prevalence Rate Globally with Key Countries

    5.3. Key Industrial Events(Licensing Partnership/Merger & Acquisition)

    5.4. Average Annual Cost of Therapy

    5.5. Reimbursement Scenario - Global Von Willebrand Disease

    5.6. Disease Overview

    5.7. Regulatory Scenario, by Region/globally

    5.8. Treatment Options For Women with Menorrhagia in Von Willebrand Disease

    5.9. Covid-19 Impact Analysis

6. Global Von Willebrand Disease Treatment Market Analysis, by Disease Type

    6.1. Introduction 

    6.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    6.3. Global Von Willebrand Disease Treatment Market Forecast, by Disease Type

        6.3.1. Type 1 Von Willebrand Disease

        6.3.2. Type 2 Von Willebrand Disease

        6.3.3. Type 3 Von Willebrand Disease

        6.3.4. Acquired Von Willebrand Disease

    6.4. Global Von Willebrand Disease Treatment Market Analysis, by Disease Type 

7. Global Von Willebrand Disease Treatment Market Analysis, by Drug

    7.1. Introduction 

    7.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    7.3. Global Von Willebrand Disease Treatment Market Forecast, by Drug

        7.3.1. Desmopressin

        7.3.2. Clot-stabilizing medications

        7.3.3. Replacement therapies

        7.3.4. Contraceptives

        7.3.5. Others

    7.4. Global Von Willebrand Disease Treatment Market Analysis, by Drug 

8. Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration

    8.1. Introduction 

    8.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    8.3. Global Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        8.3.1. Oral

        8.3.2. Injection

        8.3.3. Other

    8.4.   Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration 

9. Global Von Willebrand Disease Treatment Market Analysis, by Gender

    9.1. Introduction 

    9.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    9.3. Global Von Willebrand Disease Treatment Market Forecast, by Gender

        9.3.1. Men

        9.3.2. Women

    9.4. Global Von Willebrand Disease Treatment Market Analysis, by Route of Administration

10.   Global Von Willebrand Disease Treatment Market Analysis, by Distribution Channel

    10.1. Introduction 

    10.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    10.3. Global Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Global Von Willebrand Disease Treatment Market Analysis, by Distribution Channel

11. Global Von Willebrand Disease Treatment Market Analysis, by Region

    11.1. Global Von Willebrand Disease Treatment Market Scenario, by Region/Country

    11.2. Global Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Region

    11.3. Global Von Willebrand Disease Treatment Market Forecast, by Region

        11.3.1. North America

        11.3.2. Europe

        11.3.3. Asia Pacific

        11.3.4. Latin America

        11.3.5. Middle East & Africa

12. North America Von Willebrand Disease Treatment Market Analysis

    12.1. Key Findings

    12.2. North America Von Willebrand Disease Treatment Market Overview

    12.3. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country

    12.4. North America Von Willebrand Disease Treatment Market Forecast, by Country

        12.4.1. U.S.

        12.4.2. Canada

    12.5.  North America Von Willebrand Disease Treatment Market Value Share and Attractiveness       Analysis, by Disease Type

    12.6.  North America Von Willebrand Disease Treatment Market Forecast, by Disease Type

        12.6.1. Type 1 Von Willebrand Disease

        12.6.2. Type 2 Von Willebrand Disease

        12.6.3. Type 3 Von Willebrand Disease

        12.6.4. Acquired Von Willebrand Disease

    12.7. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    12.8. North America Von Willebrand Disease Treatment Market Forecast, by Drug

        12.8.1. Desmopressin

        12.8.2. Clot-stabilizing medications

        12.8.3. Replacement therapies

        12.8.4. Contraceptives

        12.8.5. Others

    12.9. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    12.10. North America Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        12.10.1. Oral 

        12.10.2. Injection

        12.10.3. Others

    12.11. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    12.12. North America Von Willebrand Disease Treatment Market Forecast, by Gender

        12.12.1. Men

        12.12.2. Women

    12.13. North America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.14. North America Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        12.14.1. Hospital pharmacies

        12.14.2. Retail pharmacies

        12.14.3. Online pharmacies

13. Europe Von Willebrand Disease Treatment Market Analysis

    13.1. Key Findings

    13.2. Europe Von Willebrand Disease Treatment Market Overview

    13.3. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.4. Europe Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region

        13.4.1. Germany

        13.4.2. France

        13.4.3. U.K.

        13.4.4. Italy

        13.4.5. Spain

        13.4.6. Rest of Europe

    13.5. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    13.6. Europe Von Willebrand Disease Treatment Market Forecast, by Disease Type

        13.6.1. Type 1 Von Willebrand Disease

        13.6.2. Type 2 Von Willebrand Disease

        13.6.3. Type 3 Von Willebrand Disease

        13.6.4. Acquired Von Willebrand Disease

    13.7. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    13.8. Europe Von Willebrand Disease Treatment Market Forecast, by Drug

        13.8.1. Desmopressin

        13.8.2. Clot-stabilizing medications

        13.8.3. Replacement therapies

        13.8.4. Contraceptives

        13.8.5. Others

    13.9. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    13.10. Europe Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        13.10.1. Oral 

        13.10.2. Injection

        13.10.3. Others

    13.11. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    13.12. Europe Von Willebrand Disease Treatment Market Forecast, by Gender

        13.12.1. Men

        13.12.2. Women

    13.13. Europe Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.14. Europe Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        13.14.1. Hospital pharmacies

        13.14.2. Retail pharmacies

        13.14.3. Online pharmacies

14. Asia Pacific Von Willebrand Disease Treatment Market Analysis

    14.1. Key Findings

    14.2. Asia Pacific Von Willebrand Disease Treatment Market Overview

    14.3. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.4. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region

            14.4.1.1. Japan

            14.4.1.2. China

            14.4.1.3. India

        14.4.2. Australia & New Zealand

        14.4.3. Rest of Asia Pacific

    14.5. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    14.6. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Disease Type

        14.6.1. Type 1 Von Willebrand Disease

        14.6.2. Type 2 Von Willebrand Disease

        14.6.3. Type 3 Von Willebrand Disease

        14.6.4. Acquired Von Willebrand Disease

    14.7. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    14.8. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Drug

        14.8.1. Desmopressin

        14.8.2. Clot-stabilizing medications

        14.8.3. Replacement therapies

        14.8.4. Contraceptives

        14.8.5. Others

    14.9. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    14.10. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        14.10.1. Oral 

        14.10.2. Injection

        14.10.3. Others

    14.11. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    14.12. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Gender

        14.12.1. Men

        14.12.2. Women

    14.13. Asia Pacific Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.14. Asia Pacific Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        14.14.1. Hospital pharmacies

        14.14.2. Retail pharmacies

        14.14.3. Online pharmacies

15. Latin America Von Willebrand Disease Treatment Market Analysis

    15.1. Key Findings

    15.2. Latin America Von Willebrand Disease Treatment Market Overview

    15.3. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country

    15.4. Latin America Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region

        15.4.1. Brazil

        15.4.2. Mexico

        15.4.3. Rest of Latin America

    15.5. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    15.6.  Latin America Von Willebrand Disease Treatment Market Forecast, by Disease Type

        15.6.1. Type 1 Von Willebrand Disease

        15.6.2. Type 2 Von Willebrand Disease

        15.6.3. Type 3 Von Willebrand Disease

        15.6.4. Acquired Von Willebrand Disease

    15.7. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    15.8. Latin America Von Willebrand Disease Treatment Market Forecast, by Drug

        15.8.1. Desmopressin

        15.8.2. Clot-stabilizing medications

        15.8.3. Replacement therapies

        15.8.4. Contraceptives

        15.8.5. Others

    15.9. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    15.10. Latin America Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        15.10.1. Oral 

        15.10.2. Injection

        15.10.3. Others

    15.11. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    15.12. Latin America Von Willebrand Disease Treatment Market Forecast, by Gender

        15.12.1. Men

        15.12.2. Women

    15.13. Latin America Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    15.14. Latin America Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        15.14.1. Hospital pharmacies

        15.14.2. Retail pharmacies

        15.14.3. Online pharmacies

16. Middle East & Africa Von Willebrand Disease Treatment Market Analysis

    16.1. Key Findings

    16.2. Middle East & Africa Von Willebrand Disease Treatment Market Overview

    16.3. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Country

    16.4. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Country/Sub-region

        16.4.1. GCC Countries

        16.4.2. South Africa

        16.4.3. Rest of Middle East & Africa

    16.5.   Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    16.6.   Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Disease Type

        16.6.1. Type 1 Von Willebrand Disease

        16.6.2. Type 2 Von Willebrand Disease

        16.6.3. Type 3 Von Willebrand Disease

        16.6.4. Acquired Von Willebrand Disease

    16.7. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Drug

    16.8. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Drug

        16.8.1. Desmopressin

        16.8.2. Clot-stabilizing medications

        16.8.3. Replacement therapies

        16.8.4. Contraceptives

        16.8.5. Others

    16.9. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Route of Administration

    16.10. Middle East & Africa  Von Willebrand Disease Treatment Market Forecast, by Route of Administration

        16.10.1. Oral 

        16.10.2. Injection

        16.10.3. Others

    16.11. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Gender

    16.12. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Gender

        16.12.1. Men

        16.12.2. Women

    16.13. Middle East & Africa Von Willebrand Disease Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    16.14. Middle East & Africa Von Willebrand Disease Treatment Market Forecast, by Distribution Channel

        16.14.1. Hospital pharmacies

        16.14.2. Retail pharmacies

        16.14.3. Online pharmacies

17. Competitive Landscape

    17.1. Company Profile

        17.1.1. Octapharma AG 

            17.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.1.2. Financial Overview

            17.1.1.3. Product Portfolio

            17.1.1.4. SWOT Analysis

            17.1.1.5. Strategic Overview

        17.1.2. Grifols, S.A.

            17.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.2.2. Financial Overview

            17.1.2.3. Product Portfolio

            17.1.2.4. SWOT Analysis

            17.1.2.5. Strategic Overview

        17.1.3. Shire Plc. 

            17.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.3.2. Financial Overview

            17.1.3.3. Product Portfolio

            17.1.3.4. SWOT Analysis

            17.1.3.5. Strategic Overview

        17.1.4. Bayer AG 

            17.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.4.2. Product Portfolio

            17.1.4.3. SWOT Analysis

            17.1.4.4. Strategic Overview

        17.1.5. CSL Limited 

            17.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.5.2. Financial Overview

            17.1.5.3. Product Portfolio

            17.1.5.4. SWOT Analysis

            17.1.5.5. Strategic Overview

        17.1.6. Pfizer, Inc

            17.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.6.2. Financial Overview

            17.1.6.3. Product Portfolio

            17.1.6.4. SWOT Analysis

            17.1.6.5. Strategic Overview

        17.1.7. Akorn, Inc. 

            17.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.7.2. Financial Overview

            17.1.7.3. Product Portfolio

            17.1.7.4. SWOT Analysis

            17.1.7.5. Strategic Overview

        17.1.8. Ferring B.V.

            17.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.1.8.2. Financial Overview

            17.1.8.3. Product Portfolio

            17.1.8.4. SWOT Analysis

            17.1.8.5. Strategic Overview

List of Tables

Table 01: Key Mergers & Acquisition in the Von Willebrand Disease Treatment Market

Table 02: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 03: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 04: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 05: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 06: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 07: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 08: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 09: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 10: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 11: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 12: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 13: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 14: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 15: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 16: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 17: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 18: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 19: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 20: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 21: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 22: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 23: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 24: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 25: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 26: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 27: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 28: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 29: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 30: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 31: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 32: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 33: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 34: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Drug, 2018–2030

Table 35: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 36: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Gender, 2018–2030

Table 37: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Von Willebrand Disease Treatment Market Value Share, by Disease Type, 2019

Figure 03: Global Von Willebrand Disease Treatment Market Value Share, by Drug, 2019

Figure 04: Global Von Willebrand Disease Treatment Market Value Share, by Route of Administration, 2019

Figure 05: Global Von Willebrand Disease Treatment Market Value Share, by Gender, 2019

Figure 06: Global Von Willebrand Disease Treatment Market Value Share, by Distribution Channel, 2019

Figure 07: Global Von Willebrand Disease Treatment Market Value Share, by Region, 2019

Figure 08: Regulatory Approval Process - U.S.  

Figure 09: Regulatory Approval Process - Europe 

Figure 10: Regulatory Approval Process - Japan

Figure 11: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 12: Global Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 13: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 1 Von Willebrand Disease, 2018–2030

Figure 14: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 2 Von Willebrand Disease, 2018–2030

Figure 15: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Type 3 Von Willebrand Disease, 2018–2030

Figure 16: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Acquired Von Willebrand Disease, 2018–2030

Figure 17: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 18: Global Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 19: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Desmopressin, 2018–2030

Figure 20: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Clot-stabilizing Medications, 2018–2030

Figure 21: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Replacement therapies, 2018–2030

Figure 22: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Contraceptives, 2018–2030

Figure 23: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Others, 2018–2030

Figure 24:  Global Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 25: Global Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 26: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Oral, 2018–2030

Figure 27: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Injection, 2018–2030

Figure 28: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Others, 2018–2030

Figure 29: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

 Figure 30: Global Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

List of Figure 

Figure 31: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Men, 2018–2030

Figure 32: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Injection, 2018–2030

Figure 33:  Global Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 34: Global Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 35: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Hospital Pharmacies, 2018–2030

Figure 36: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Retail Pharmacies, 2018–2030

Figure 37: Global Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast, by Online Pharmacies, 2018–2030

Figure 38: Global Von Willebrand Disease Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 39: Global Von Willebrand Disease Treatment Market Attractiveness Analysis, by Region

Figure 40: North America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 41: North America Von Willebrand Disease Treatment Market Value Share (%), by Country, 2019 and 2030

Figure 42: North America Von Willebrand Disease Treatment Market Attractiveness, by Country, 2020–2030

Figure 43: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 44: North America Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 45: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 46: North America Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 47: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 48: North America Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 49: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

Figure 50: North America Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

Figure 51: North America Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 52: North America Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 53: Europe Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Europe Von Willebrand Disease Treatment Market Value Share (%), by Countries/Sub-region, 2019 and 2030

Figure 55: Europe Von Willebrand Disease Treatment Market Attractiveness, by Countries/Sub-region, 2020–2030

Figure 56: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 57: Europe Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 58: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 59: Europe Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 60: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 61: Europe Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 62: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

Figure 63: Europe Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

Figure 64: Europe Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 65: Europe Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 66: Asia Pacific Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 67: Asia Pacific Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 68: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 69: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 70: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 71: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 72: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 73: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 74: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 75: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

Figure 76: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

Figure 77: Asia Pacific Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 78: Asia Pacific Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 79: Latin America Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 80: Latin America Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 81: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 82: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 83: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 84: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 85: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 86: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 87: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 88: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

Figure 89: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

Figure 90: Latin America Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 91: Latin America Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 92: Middle East & Africa Von Willebrand Disease Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 93: Middle East & Africa Von Willebrand Disease Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 94: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 95: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 96: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Disease Type, 2020–2030

Figure 97: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Drug, 2019 and 2030

Figure 98: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Drug, 2020–2030

Figure 99: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 100: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 101: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Gender, 2019 and 2030

Figure 102: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Gender, 2020–2030

Figure 103: Middle East & Africa Von Willebrand Disease Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 104: Middle East & Africa Von Willebrand Disease Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved